SCHEMBL21802018

SCHEMBL21802018

O=C(NCCCCN1CCN(c2ccc(F)cc2F)CC1)Nc1cnc2ccccc2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
DRD3 P35462 13/20 0.55
DRD2 P14416 11/20 0.55
HTR2A P28223 6/20 0.55
HTR2C P28335 6/20 0.55
HTR1A P08908 5/20 0.55
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
MAPT P10636 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX15 P16050 1/20 0.51
CYP2C19 P33261 1/20 0.51
ADRA1A P35348 2/20 0.50
HTR7 P34969 1/20 0.49
MAPK1 P28482 1/20 0.48
FAAH O00519 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21802015 0.93 DRD3 (0.56) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802095 0.93 LMNA (0.67) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802148 0.89 DRD3 (0.59) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802020 0.88 DRD3 (0.55) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802154 0.86 DRD2 (0.67) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802152 0.86 SLC6A4 (0.60) DRD3DRD2HTR2AHTR2CHTR1A
SCHEMBL21802157 0.86 LMNA (0.53) LMNANPSR1DRD3DRD2HTR2A
SCHEMBL21802155 0.83 DRD2 (0.75) DRD3DRD2HTR2AHTR2CHTR1A
SCHEMBL21802147 0.82 HTR7 (0.66) LMNADRD3DRD2HTR2AHTR2C
SCHEMBL21802141 0.82 HTR7 (0.65) DRD3DRD2HTR2AHTR2CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-06-03 US claimed
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) 2020-03-19 US claimed
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-06-03 US disclosed
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) 2020-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF DRD3, DRD2, PRLHR LMNA 3873/4885NPSR1 75/4885DRD3 1/4885
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof DRD3, DRD2, PRLHR LMNA 3843/4885NPSR1 67/4885DRD3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.